Korro Bio, Inc. Payments of Financing Costs
Korro Bio, Inc. (KRRO) reported Payments of Financing Costs of $2.46 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2020-11-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2020-11-16
- 2019-09-30: Payments of Financing Costs 9 month $2.46M.
| Period end | Payments of Financing Costs 9 month |
|---|---|
| 2019-09-30 | $2.46M 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |